Pascal Biosciences – New Cancer Treatments Emerging from Pioneering Cannabinoid Discoveries
Ryan Allway
July 23rd, 2019
App, Exclusive, News, Top News
CFN’s Exclusive Interview with CEO Dr. Patrick Gray
The cannabis industry is projected to reach $75 billion by 2030. While many investors are familiar with cultivators and dispensaries, there could be an even greater opportunity on the medical side. Cannabinoids could displace blockbuster drugs and provide medical breakthroughs.
CFN Media recently interviewed Pascal Biosciences Inc. (TSX-V: PAS) CEO Dr. Patrick W. Gray to discuss how the company is harnessing the power of cannabis to develop cancer therapeutics.
CFN Media: There are a lot of health benefits identified for Cannabis, including treating pain, anxiety, depression, spasticity, epilepsy, and insomnia. What is the focus of Pascal Biosciences?
Dr. Patrick W. Gray: “Pascal is focused on discovering new cancer therapeutics. In the past, THC and CBD have been shown to improve cancer symptoms like pain, nausea, and appetite. Pascal is discovering and developing new drugs that directly attack cancer and work with other drugs to eliminate tumors.
CFN Media: Can you describe the groundbreaking research that put Pascal on the map for cannabinoid research in cancer?
Dr. Patrick W. Gray: “Pascal is the first company to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy for cancer. More specifically, we have discovered certain cannabinoids that enhance the recognition of tumor cells by the immune system. This discovery is important because the leading class of new cancer fighting agents, termed “checkpoint inhibitors”, activates the immune system to destroy cancer cells. Enhancing recognition of cancer cells with cannabinoids may greatly improve the efficacy of this drug class.
Click here to Receive News Alerts from Pascal Biosciences
Since that announcement, we have since analyzed 400 cannabinoids–natural, synthetic, and endogenous—and identified even more potent structures. In additional efforts for advancement, we have partnered with one of the pre-eminent research teams in cannabinoids through an exclusive license agreement with the University of Washington (UW) in Seattle. This program, developed in the lab of renowned cannabis researcher Dr. Nephi Stella, founder of the UW Center for Cannabis Research, includes our lead therapeutic, PAS-403, a cannabinoid-based drug for the treatment of glioblastoma and brain metastases.”
CFN Media: Can you tell us more about your cannabinoid-derived glioblastoma treatment?
Dr. Patrick W. Gray: “Glioblastoma is a devastating brain cancer with limited therapeutic options. We have made great progress with our drug PAS-403. We have developed an efficient manufacturing process, completed biochemical safety studies, examined pharmacological properties, and studied activity on both normal and tumor cells. Our efforts continue to support the use of PAS-403 for testing in glioblastoma patients: the compound is active against human glioblastoma cells in culture, accumulates in the brain, has a good safety profile against other targets, and has synergistic activity with standard of care in an animal model. With input from our Clinical Advisory Board, we have developed a clinical plan for testing PAS-403 in glioblastoma patients.”
Click here to Receive News Alerts from Pascal Biosciences
CFN Media: Would you please provide additional information about Pascal’s outstanding Clinical Advisory Board?
Dr. Patrick W. Gray: “We are very fortunate to have assembled a group of world-renowned researchers and clinicians in the field of neuro-oncology. These doctors have great experience treating patients, and they are anxious to help develop new products for glioblastoma. Our team at Pascal was impressed by their drive to find a cure for glioblastoma and also by their enthusiasm for PAS-403. Only three new treatments have been approved in the last 30 years for glioblastoma. After reviewing our data, our CAB has strongly encouraged us to proceed with PAS-403 clinical trials to make advancements for this devastating disease.”
Members of Pascal’s esteemed advisory group include:
*Chairman Dr. Darell Bigner of Duke University School of Medicine, a preeminent brain tumor researcher who is founding director of the Preston Robert Tish Brain Tumor Center.
*Dr. Mitchel Berger of UCSF, an internationally recognized expert in treating brain tumors.
*Dr. Timothy Cloughesy, of UCLA, director of the UCLA Nero-Oncology Program.
*Dr. Patrick Wen of Harvard Medical School and Director of the Center for Neuro-Oncology, Dana Farber Cancer Research Institute and Director of the Division of Cancer Neurology at Brigham and Women’s Hospital; President of the Society for Neuro-Oncology.
*Dr. Andrew Sloan of the Departments of Neurological Surgery and of Pathology, School of Medicine, Case Western Reserve University, Director of the Brain Tumor and Neuro-Oncology Center at the Seidman Cancer Center
CFN Media: What are some of the key upcoming catalysts that shareholders can look forward to? Where do your clinical programs stand at this point in time?
Dr. Patrick W. Gray: “Our cannabinoid-based program for glioblastoma is expected to begin human clinical trials, a significant milestone for the company. In addition, our immune surveillance program is progressing nicely with some exciting discoveries. We will report our advancements in the scientific literature, at international conferences, and in press releases. Investors can expect updates on our programs in a timely fashion, because we have a lot of exciting information to share!”
CFN Media: Why should investors consider your stock?
Dr. Patrick W. Gray: “Pascal has an exciting pipeline developing cannabinoid therapeutics for cancer. Cannabinoid-based medicines are a fast-growing opportunity given the legalization of cannabis in Canada. The current competitive landscape for biotechnology companies developing cannabinoid therapeutics is small with diverse indications. Pascal stands out as one of the few companies targeting glioblastoma and, more broadly, cancer in combination with checkpoint inhibitors. Our utmost priority is to help patients suffering from life-threatening diseases, and we strongly believe that our current portfolio can make an impact on patient lives.”
CFN Media: Thank you for taking the time to speak with us Dr. Gray.
About Pascal Biosciences Inc.
Pascal Biosciences Inc. (TSX-V:PAS) is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.
To learn more visit: https://www.pascalbiosciences.com/
Click here to Receive News Alerts from Pascal Biosciences
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Jacksam/Convectium designs and markets proprietary automated vape, POD and cartridge filling/capping equipment for the cannabis industry.
Headquartered in Lakewood, Colo., STWC Holdings is a complete ecosystem of entities and services that support the burgeoning cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
